Compare Bristol-Myers Squibb Co (BMY) vs Coursera Inc (COUR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Coursera Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.81 (market cap $129.94B), while Coursera Inc trades at $5.56 (market cap $1.50B). The key difference: Bristol-Myers Squibb Co is far larger — about 86.6× Coursera Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Coursera Inc pays none. Which is the better fit depends on your goals.
| BMY | COUR | |
|---|---|---|
Market Cap | $129.94B | $1.50B |
Sector | Health | Consumer Staples |
52-Week High | $65.89 | $12.20 |
52-Week Low | $42.60 | $5.09 |
Enterprise Value | $163.92B | $759.54M |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Coursera (COUR) trades at $5.525, down 4.08% today, with a bearish technical signal from moving averages. Revenue grew to $757.5M in 2025, but net losses persist at -$51M. Recent Q2 2026 earnings beat expectations at $0.17 EPS, and the company made a $100M strategic investment in AI education firm LearnVector (Business Wire, July 28, 2026).
The stock offers upside to the $7.70 consensus price target, supported by a majority buy rating from analysts. However, profitability challenges and competitive pressures in online education pose risks. Positive cash flow trends and institutional interest provide a foundation for recovery if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →
